Literature DB >> 15077163

PRDM5 is silenced in human cancers and has growth suppressive activities.

Qingdong Deng1, Shi Huang.   

Abstract

Several genes that contain the PR (PRDI-BF1 and RIZ) domain have been linked with human cancers. We describe here a new PR-domain-containing gene designated as PRDM5 (PFM2). A PRDM5 cDNA was isolated based on its homology to the PR domain of RIZ1 (PRDM2). The gene encodes an open reading frame of 630 amino acids and contains a PR domain in the NH-terminal region followed by 16 zinc finger motifs. Radiation hybrid analysis mapped PRDM5 to human chromosome 4q26, a region thought to harbor tumor suppressor genes for breast, ovarian, liver, lung, colon, and other cancers. The gene has a CpG island promoter and is silenced in human breast, ovarian, and liver cancers. A recombinant adenovirus expressing PRDM5 caused G2/M arrest and apoptosis upon infection of tumor cells. These results suggest that inactivation of PRDM5 may play a role in carcinogenesis. Copyright 2004 Nature Publishing Group

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15077163     DOI: 10.1038/sj.onc.1207615

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  45 in total

Review 1.  Histone methyltransferases: novel targets for tumor and developmental defects.

Authors:  Xin Yi; Xue-Jun Jiang; Xiao-Yan Li; Ding-Sheng Jiang
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

2.  PRDM6 is enriched in vascular precursors during development and inhibits endothelial cell proliferation, survival, and differentiation.

Authors:  Yaxu Wu; James E Ferguson; Hong Wang; Rusty Kelley; Rongqin Ren; Holly McDonough; James Meeker; Peter C Charles; Hengbin Wang; Cam Patterson
Journal:  J Mol Cell Cardiol       Date:  2007-06-30       Impact factor: 5.000

3.  Genomic and proteomic analyses of Prdm5 reveal interactions with insulator binding proteins in embryonic stem cells.

Authors:  Giorgio Giacomo Galli; Matteo Carrara; Chiara Francavilla; Kristian Honnens de Lichtenberg; Jesper Velgaard Olsen; Raffaele Adolfo Calogero; Anders Henrik Lund
Journal:  Mol Cell Biol       Date:  2013-09-16       Impact factor: 4.272

Review 4.  Histone demethylases and cancer.

Authors:  Sotirios C Kampranis; Philip N Tsichlis
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

Review 5.  DNA methylation patterns as noninvasive biomarkers and targets of epigenetic therapies in colorectal cancer.

Authors:  Yutaka Hashimoto; Timothy J Zumwalt; Ajay Goel
Journal:  Epigenomics       Date:  2016-04-22       Impact factor: 4.778

6.  Direct interaction between the PRDM3 and PRDM16 tumor suppressors and the NuRD chromatin remodeling complex.

Authors:  Danton Ivanochko; Levon Halabelian; Elizabeth Henderson; Pavel Savitsky; Harshika Jain; Edyta Marcon; Shili Duan; Ashley Hutchinson; Alma Seitova; Dalia Barsyte-Lovejoy; Panagis Filippakopoulos; Jack Greenblatt; Evelyne Lima-Fernandes; Cheryl H Arrowsmith
Journal:  Nucleic Acids Res       Date:  2019-02-20       Impact factor: 16.971

7.  PRISM/PRDM6, a transcriptional repressor that promotes the proliferative gene program in smooth muscle cells.

Authors:  Christopher A Davis; Michael Haberland; Michael A Arnold; Lillian B Sutherland; Oliver G McDonald; James A Richardson; Geoffrey Childs; Stephen Harris; Gary K Owens; Eric N Olson
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

8.  Methylation of PRDM2, PRDM5 and PRDM16 genes in lung cancer cells.

Authors:  Shuang-Xiang Tan; Rui-Cheng Hu; Jing-Jing Liu; Yong-Li Tan; Wen-En Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

Review 9.  Leukemogenesis of the EVI1/MEL1 gene family.

Authors:  Kazuhiro Morishita
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

10.  The tumor suppressor PRDM5 regulates Wnt signaling at early stages of zebrafish development.

Authors:  Natalia Meani; Federica Pezzimenti; Gianluca Deflorian; Marina Mione; Myriam Alcalay
Journal:  PLoS One       Date:  2009-01-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.